8-KOther Events

VERTEX PHARMACEUTICALS INC / MA 8-K Report, Corporate Update (Jun 27, 2024)

Filed June 27, 2024For Securities:VRTX

Summary

Vertex Pharmaceuticals Inc. (VRTX) filed an 8-K on June 27, 2024, to provide an update on the accounting treatment and financial impact of its previously announced acquisition of Alpine Immune Sciences, Inc. The company expects to account for the acquisition as an asset acquisition, which will result in a significant one-time, non-deductible Acquired In-Process Research & Development (AIPR&D) expense of approximately $4.4 billion in the second quarter of 2024. This expense will impact both GAAP and non-GAAP reported operating expenses and net income, and will influence the company's financial guidance for the full year 2024. In addition to the AIPR&D charge, Vertex anticipates incurring approximately $200 million in transaction-related compensation expense due to the acceleration of unvested Alpine awards. This compensation expense will also affect reported GAAP operating expenses and net income for the current quarter and the full year. Despite these significant non-recurring charges, Vertex reaffirms its expectation to absorb Alpine's non-GAAP R&D and SG&A expenses within its previously provided operating expense guidance range for the remainder of 2024.

Key Highlights

  • 1Vertex Pharmaceuticals expects to record a one-time, non-deductible Acquired In-Process R&D (AIPR&D) expense of approximately $4.4 billion for the Alpine acquisition in Q2 2024.
  • 2An additional $200 million in transaction-related compensation expense is expected in Q2 2024 due to the acceleration of unvested Alpine awards.
  • 3Both the AIPR&D expense and the compensation expense will impact reported GAAP and non-GAAP operating expenses and net income for Q2 and full-year 2024.
  • 4The company expects these charges to affect its full-year 2024 financial guidance.
  • 5Vertex will account for the Alpine acquisition as an asset acquisition.
  • 6The company anticipates absorbing Alpine's non-GAAP R&D and SG&A expenses for the rest of 2024 within previously issued guidance.
  • 7The filing includes forward-looking statements regarding the accounting treatment and financial impact, subject to risks and uncertainties.

Frequently Asked Questions